GangaGen is a highly innovative brand specializing in the development of novel treatments for drug-resistant bacterial infections. Led by a competent and experienced management team, the company is at the forefront of scientific advancements in protein antibacterials and bacteriophages. GangaGen's protein antibacterials, including bacteriocins, lysins, and ectolysin P128, have proven to be effective in combating a wide range of bacteria.

These cutting-edge solutions offer a promising alternative to traditional antibiotics and have the potential to revolutionize the field of infection treatment. In addition to protein antibacterials, GangaGen is also actively researching and developing bacteriophages. These naturally occurring viruses have shown great potential in targeting specific bacterial strains and have the ability to overcome drug resistance.

Committed to innovation and collaboration, GangaGen offers collaborative research services for partners interested in advancing the fight against antibiotic-resistant infections. With a focus on transparency and scientific excellence, the brand keeps a finger on the pulse of industry developments through its media presence, news, and events. Contact GangaGen today to explore potential partnerships and contribute to the critical mission of combating drug-resistant bacteria